Pediatrics at CU School of Medicine is among the best in the nation! World-class pediatric residency program and research facilities. Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado

Academic Training in Pediatric Pulmonary Diseases: National Institutional Research Service Award⁺
Principal Investigator: Steven H. Abman, MD
Source: National Institutes of Health - HL07670-16
Amount: $1,800,000
Term: 2004-2009

Clinical Proteomics Center in Lung Disease
Principal Investigator: Frank J. Accurso, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - U01HL081335-01
Amount: $4,216,147
Term: 2005-2009

• Core A: Administrative
  Principal Investigator: Frank J. Accurso, MD
  Amount: $475,296
  
• Core B: Clinical
  Principal Investigator: Steven H. Abman, MD
  Co-Investigator: John P. Kinsella, MD
  Co-Investigator: D. Dunbar Ivy, MD
  Amount: $908,829
  
• Core C: Data Management
  Principal Investigator: Gary O. Zerbe, PhD
  Amount: $913,363
  
• Core D: Laboratory
  Principal Investigator: Mark W. Duncan, PhD
  Amount: $1,268,104
  
• Core E: Educational
  Principal Investigator: Laurie A. Shroyer, PhD
  Co-Investigator: Robin R. Deterding, MD
  Amount: $650,555
  

Determinants of Early Pancreatic Injury in Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: National Institutes of Health - 1 R01 DK57755-027
Amount: $578,904
Term: 2001-2005

Cystic Fibrosis Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - C017-05
Amount: $195,626
Term: 2005-2006

Cystic Fibrosis Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - C017-04
Amount: $229,490
Term: 2004-2005

Cystic Fibrosis First-Year Clinical Fellowship for Jerimiah Lysinger, MD
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - LYSING05B0
Amount: $42,000
Term: 2005-2006

Cystic Fibrosis First-Year Clinical Fellowship for Edith Towler-Zemanick, MD
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - TOWLER04B0
Amount: $42,000
Term: 2004-2005

A Multicenter, Double-Blind, Placebo-Controlled, Phase II Study of Aerosolized tgAAVCF for the Treatment of Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Seattle Children's Hospital and Regional Medical Center (Cystic Fibrosis Foundation Therapeutics, Inc.)
Estimated Amount: $54,680
Term: 2004-2005

Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $35,151
Term: 2005-2006

The EPIC Observational Study: Longitudinal Assessment of Risk Factors for and Impact of Pseudomonas Aeruginosa Acquisition and Early Anti-Pseudomonal Treatment in Children with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $21,477
Term: 2005-2010

Assessment of Induced Sputum as a Tool to Evaluate Anti-Inflammatory Agents in Patients with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation
Amount: $72,520
Term: 2004-2006

A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial with Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients with Pulmonary Pseudomonas Aeruginosa Requiring Frequent Antibiotics (AIR CF2)
Principal Investigator: Frank J. Accurso, MD
Source: CORUS Pharmaceuticals, Inc.
Amount: $61,013
Term: 2005

A Phase 3, Open-label, Follow-Up Study of Multiple Courses of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients (AIR CF3)
Principal Investigator: Frank J. Accurso, MD
Source: CORUS Pharmaceuticals, Inc.
Amount: $54,083
Term: 2005-2006

A Study of the Safety and Pharmacokinetics of 552-02 Following Fourteen Days of Dosing by Inhalation in Patients with Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Parion Sciences, Inc.
Amount: $29,822
Term: 2005

A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: PTC Therapeutics, Inc.
Amount: $67,253
Term: 2005-2006

Epidemiologic Study of Cystic Fibrosis: A Multicenter, Longitudinal Follow-Up Study of Patients with Cystic Fibrosis for Monitoring Pulmonary Function, Pulmonary Exacerbations and the Safety of Long-Term Treatment with Pulmozyme (Dornase Alfa)
Principal Investigator: Frank J. Accurso, MD
Source: Genentech, Inc.
Amount: $343,253
Term: 1994-present

The Role of Vascular Endothelial Growth Factor and Nitric Oxide in Lung Vascular Development⁺
Principal Investigator: Vivek Balasubramaniam, MD
Source: National Institutes of Health - 1 K08 HL073893-01
Amount: $653,400
Term: 2003-2008

INO Therapeutics Research Grant
Principal Investigator: Vivek Balasubramaniam, MD
Source: INO Therapeutics
Amount: $40,000
Term: 2004-2006

Colorado State Tobacco Education and Prevention Partnership
Principal Investigator: Keith L. Cavanaugh, MD
Source: State of Colorado
Amount: $96,228
Term: 2005-2006

Recommendations for the Evaluation, Diagnosis, and Treatment of the Child with Suspected Interstitial Lung Disease
Principal Investigator: Geoff Kurland, MD
Co-Principal Investigator: Robin R. Deterding, MD
Source: American Thoracic Society
Amount: $12,500
Term: 2005-2006

A Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Pediatric Patients with Cystic Fibrosis Lung Disease
Principal Investigator: Robin R. Deterding, MD
Source: Inspire Pharmaceuticals, Inc.
Amount: $39,365
Term: 2005

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Cystic Fibrosis Lung Disease
Principal Investigator: Robin R. Deterding, MD
Source: Inspire Pharmaceuticals, Inc.
Amount: $123,589
Term: 2005-2006

Serum Biomarkers and Risk Factors for Alzheimer's Disease
Principal Investigator: Mark W. Duncan, PhD
Source: Orentreich Foundation
Amount: $50,000
Term: 2005-2006

Practical Utility of Desorption Mass Spectroscopy Techniques
Principal Investigator: Mark W. Duncan, PhD
Source: Pfizer, Inc.
Amount: $199,091
Term: 2004-2005

Control of Bacterial Toxins by Viruses and Plasmids
Principal Investigator: Randall Holmes, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - R37 AI014107-3Q
Amount: $2,462,582
Term: 2005-2010

Viability Assay for Human Islet Transplantation
Principal Investigator: Mark Nicolls, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - R21 DK070203-02
Amount; $770,000
Term: 2004-2006

Cancer Center Core Grant⁺⁺
Principal Investigator: Paul Bunn, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - P30 CA046934-17
Amount: $12,141,528
Term: 1988-2006

Mental Retardation and Development Disabilities Research Center⁺⁺
Principal Investigator: Stephen I. Goodman, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - P30 HD004024-35
Amount: $3,709,360
Term: 2003-2008

Phospholipid Dynamics in Membrane Assembly⁺⁺
Principal Investigator: Dennis Voelker, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - R37 GM032453-21
Amount: $2,500,000
Term: 2004-2008

Protein Expression Analysis in Cystic Fibrosis⁺⁺
Principal Investigator: Mark W. Duncan, PhD
Source: Cystic Fibrosis Foundation
Amount: $871,604
Term: 2002-2005

Growth Factors and Signaling Pathways in Pulmonary Fibrosis⁺⁺
Principal Investigator: Scott Worthen, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 HL073720-01
Amount: $2,561,838
Term: 2003-2007

Osmoregulated Proteins in the Inner Medulla⁺⁺
Principal Investigator: Thomas Berl, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 DK66544-01
Amount: $250,000
Term: 2004-2009

Molecular Mechanism and Role of Corneal Adlehyde Dehydrogenase⁺⁺
Principal Investigator: Vasilis Vasiliou, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 EY011490-06
Amount: $225,000
Term: 2004-2009

Practical Utility of Desorption Mass Spectroscopy Techniques⁺⁺
Principal Investigator: Mark W. Duncan, PhD
Source: Pfizer, Inc.
Amount: $199,091
Term: 2004-2005

Modulation of Inflammation by Cholesterol and 3-Hydroxy-3 Coenzyme A Reductase Inhibitors: Role of the Lipid Raft⁺⁺
Principal Investigator: Michael Fessler, MD
Co-Investigator: Mark W. Duncan, PhD
Source: American Heart Association
Amount: $197,000
Term: 2002-2007

Proteomics for Testing Hypotheses about Down Syndrome⁺⁺
Principal Investigator: David Patterson, PhD
Principal Investigator: Mark W. Duncan, PhD (Consortium Subcontractor)
Source: National Institutes of Health - RO1 NS051539-01 A1
Amount: $770,000
Term: 2004-2008

Redefining the Major Peanut Allergens⁺⁺
Principal Investigator: Stephen Dreskin, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health, National Institute of Allergy and Infectious Diseases - 5 R01 AI052164-03
Amount: $500,000
Term: 2003-2006

Myocardial Myotonic Dystophy Protein Kinase Function⁺⁺
Principal Investigator: Benjamin Perryman, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - R01 HL064136-04
Amount: $445,950
Term: 2001-2005

Chemoprevention of Early Pulmonary Lesions in Mice by Anti-Inflammatory Drugs⁺⁺
Principal Investigator: Al Malkinson, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health, National Cancer Institute - 5 R01 CA096133-02
Amount: $340,245
Term: 2002-2005

Development and Regeneration of the Endocrine Pancreas⁺⁺
Principal Investigator: John Hutton, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases - 5 U19 DK061248-03
Amount: $988,732
Term: 2001-2004

Validation of Protein Biomarkers in Cystic Fibrosis
Principal Investigator: Steven W. Hunsucker, PhD
Source: Cystic Fibrosis Foundation - HUNSUC05A0
Amount: $258,034
Term: 2005-2008

Spirometry as an Outcome Measure in Preschool Children with Cystic Fibrosis
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Cystic Fibrosis Foundation
Amount: $920,504
Term: 2004-2007

Evaluation of Pulmonary Function Tests from Raised Lung Volumes as Outcome Measures for Clinical Trials in Infants with Cystic Fibrosis
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Seattle Children's Hospital and Regional Medical Center (Cystic Fibrosis Foundation)
Amount: $113,410
Term: 2003-2005

Neuro-Immune Interactions in Developing Airways**
Principal Investigator: Gary L. Larsen, MD
Source: National Institutes of Health - R01 HL67818
Amount: $225,000/yr
Term: 2002-2006

Childhood Asthma Research and Education (CARE) Network
Principal Investigator: Stanley J. Szefler, MD
Co-Investigators: Ronina A. Covar, MD, Gary L. Larsen, MD, and Marzena Krawiec, MD
Source: National Institutes of Health - HL64288
Amount: $4,732,241
Term: 2004-2006

Noninvasive Biomarkers of Proteolytic Activity in Cystic Fibrosis
Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health - K23 RR018611-01
Amount: $653,400
Term: 2003-2008

Genetic Disorders of Mucociliary Clearance
Principal Investigator: Michael R. Knowles, MD
Site Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health - ORD #1 U54 RR019480-01
Amount: $6,250,000
Amount (Site Funding): $390,776
Term: 2004-2009

Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis
Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health, General Clinical Research Center, and INO Therapeutics, Inc. - INOT50
Amount: $34,020
Term: 2004-2006

SCOR Grant: The Impact of Injury on the Immature Pulmonary Circulationº
Principal Investigator: Kurt R. Stenmark, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - P50 HL 57144
Amount: $6,415,929
Term: 2001-2006

• Project I: G-Proteins in Hypoxic Pulmonary Vascular Remodeling
  Principal Investigator: Kurt R. Stenmark, MD
  Amount: $2,076,662
  
• Project II: Inhaled NO and the Prevention of BPD
  Principal Investigator: Steven H. Abman, MD
  Co-Investigator: John P. Kinsella, MD
  Amount: $1,860,606
  
• Project III: Prx Homeobox Genes in Pulmonary Vascular Homeostasis
  Principal Investigator: Peter L. Jones, PhD
  Amount: $1,456,087
  
• Clinical Core
  Principal Investigator: John P. Kinsella, MD
  Co-Investigator: Steven H. Abman, MD
  Amount: $481,196
  
• Administrative Core
  Principal Investigator: Kurt R. Stenmark, MD
  Amount: $543,369
  

Assessment of Induced Sputum as a Tool to Evaluate Anti-Inflammatory Agents in Patients with Cystic Fibrosis
Principal Investigator: Jeffrey S. Wagener, MD
Source: Seattle Children's Hospital and Regional Medical Center
Amount (projected): $72,520
Term: 2004-2005

Bioavailability of Yasoo Formulation: A Pharmacokinetic Study
Principal Investigator: Jeffrey S. Wagener, MD
Source: Yasoo Health, Inc. - Yasoo-003
Amount (projected): $67,436
Term 2004-2005

A Phase 2, Randomized, Double-Blind, Parallel Dose-Ranging Study of Oral TheraCLEC-Total In Cystic Fibrosis Subjects with Exocrine Pancreatic Insufficiency (TC-2A)
Principal Investigator: Jeffrey S, Wagener, MD
Source: Altus Biologics, Inc.
Amount: $182,955
Term: 2004-2005

A Phase 1 Single-Dose, Dose-Escalation Trial Comparing Safety, Pharmacokinetics, and Delivery Time of Tobramycin Powder for Inhalation (TPI Powder) Administered by the Nektar T-326 Dry Powder Inhaler Device (T-326 Inhaler) to Tobramycin Solution for Inhalation (TOBI^® at 300 mg/5 ml) Administered by a PARI LC PLUS™ Jet Nebulizer/DeVilbiss PulmoAide™ Compressor in Cystic Fibrosis (CF) Patients
Principal Investigator: Jeffrey S. Wagener, MD
Source: Chiron Pharmaceuticals, Inc.
Amount: $37,810
Term: 2003-2005

Treatment of Cystic Fibrosis Patients with Antioxidant Solution: A Pilot Study
Principal Investigator: Jeffrey S. Wagener, MD
Source: Yasoo Health, Inc.
Amount: $67,436
Term: 2004-2005

National Institutes of Health, National Heart Lung and Blood Institute, Collaborative Program in Bronchopulmonary Dysplasia**
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health, National Heart Lung and Blood Institute - 3 U01 HL 56263
Amount: $951,028
Term: 2003-2007

Mechanisms of Particulate-Induced Lung Injury (Project IV)**
Principal Investigator: Robert J. Mason, MD
Site Investigator: Carl W. White, MD
Source: Environmental Protection Agency - CR83084601
Amount: $83,840
Term: 2005-2006

Thioredoxin as a Mucolytic Agent in Cystic Fibrosis**
Principal Investigator: Carl W. White, MD
Source: Karasik Foundation
Amount: $35,000
Term: 2005-2006

Lung Epithelial Cell Survival Signaling in Ozone in Cystic Fibrosis and Normals**
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health - 1 R01 ES014448-01
Amount: $1,068,750
Term: 2005-2010

NOT-NS Medical Countermeasures to Chemical Terrorism**
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health - Supplemental ES012504
Amount: $78,000
Term: 2005-2006

Academic Training in Pediatric Pulmonary Diseases: National Institutional Research Service Award⁺
Principal Investigator: Steven H. Abman, MD
Source: National Institutes of Health - HL07670-16
Amount: $1,800,000
Term: 2004-2009

Academic Training in Pediatric Pulmonary Diseases: National Institutional Research Service Award⁺
Principal Investigator: Steven H. Abman, MD
Source: National Institutes of Health - HL07670-12
Amount: $1,605,925
Term: 1999-2004

Role of NO in the Regulation of Fetal Pulmonary Vasoreactivity and Growth*⁺
Principal Investigator: Steven H. Abman, MD
Source: March of Dimes Birth Defects Foundation - 6-FY00-124
Amount: $351,200
Term: 2000-2003

Inhaled Nitric Oxide in the Prevention of Chronic Lung Disease⁺
Principal Investigator: John P. Kinsella, MD
Co-Investigators: Steven H. Abman, MD, and Adam A. Rosenberg, MD
Source: National Institutes of Health, National Heart, Lung and Blood
Institute - R01 HL64857-01A1
Amount: $7,080,990
Term: 2000-2004

Determinants of Early Pancreatic Injury in Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: National Institutes of Health - 1 R01 DK57755-027
Amount: $2,287,423
Term: 2001-2005

Effects of Pseudomonas aeruginosa on Inflammatory Gene Expression
Principal Investigator: David Rodman, MD
Co-Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - CFFPN0004-071
Amount: $1,500,000
Term: 2001-2004

Airway Clearance in Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - ACCURS98AO
Amount: $876,805
Term: 1999-2004

Cystic Fibrosis Therapeutic Development Center
Amount (Site Funding): Frank J. Accurso, MD
Co-Investigator: Jeffrey S. Wagener, MD
Source: Cystic Fibrosis Foundation - ACCURS98YO
Amount: $809,770
Term: 1998-2003

Project I-Airway Epithelial Cell Genomics and Pseudomonas aeruginosa Infection in Cystic Fibrosis
Principal Investigator: David Rodman, MD
Project I Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - CFFRODMAN00V0
Amount (Funding for Project 1): $375,000
Term: 2001-2004

Cystic Fibrosis Center Grant
Principal Investigator: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - C017-03
Amount: $221,254
Term: 2003-2004

A Multicenter, Double-Blind, Placebo-Controlled, Phase II Study of Aerosolized tgAAVCF for the Treatment of Cystic Fibrosis
Principal Investigator: Frank J. Accurso, MD
Source: Seattle Children's Hospital and Regional Medical Center (Cystic Fibrosis Foundation Therapeutics, Inc.)
Estimated Amount: $54,680
Term: 2004-2005

Cystic Fibrosis First-Year Clinical Fellowship for Theresa Laguna, MD
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - LAGUNA03B0
Amount: $42,000
Term: 2003-2004

Cystic Fibrosis First-Year Clinical Fellowship for Edith Towler-Zemanick, MD
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - TOWLER04B0
Amount: $42,000
Term: 2004-2005

The Role of Vascular Endothelial Growth Factor and Nitric Oxide in Lung Vascular Development⁺
Principal Investigator: Vivek Balasubramaniam, MD
Source: National Institutes of Health - 1 K08 HL073893-01
Amount: $653,400
Term: 2003-2008

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of INS37217 Inhalation Solution in Subjects with Mild to Moderate Cystic Fibrosis Lung Disease
Principal Investigator: Robin R. Deterding, MD
Source: Cystic Fibrosis Foundation Therapeutics Network
Amount: $99,057
Term: 2002-2003

Responsive Virtual Human Technology Research National Science Foundation Grant
Principal Investigator: Robin R. Deterding, MD
Source: Research Triangle Institute - NSF 00-126
Amount: $42,704
Term: 2001-2004

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Cystic Fibrosis Lung Disease
Principal Investigator: Robin R. Deterding, MD
Sources: Inspire Pharmaceuticals, Inc.
Amount: $37,627
Term: 2004-2005

Cancer Center Core Grant⁺⁺
Principal Investigator: Paul Bunn, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - P30 CA046934-17
Amount: $12,141,528
Term: 2001-2006

Mental Retardation and Development Disabilities Research Center⁺⁺
Principal Investigator: Linda S. Crnic, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - P30 HD004024-35
Amount: $3,709,360
Term: 2003-2008

Phospholipid Dynamics in Membrane Assembly⁺⁺
Principal Investigator: Dennis Voelker, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - R37 GM032453-21
Amount: $2,500,000
Term: 2004-2008

Protein Expression Analysis in Cystic Fibrosis⁺⁺
Principal Investigator: Mark W. Duncan, PhD
Source: Cystic Fibrosis Foundation
Amount: $871,604
Term: 2002-2005

Redefining the Major Peanut Allergens⁺⁺
Principal Investigator: Stephen Dreskins, MD, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 AI052164-2
Amount: $500,000
Term: 2003-2005

Growth Factors and Signaling Pathways in Pulmonary Fibrosis⁺⁺
Principal Investigator: Scott Worthen, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 HL073720-01
Amount: $475,000
Term: 2003-2007

Osmoregulated Proteins in the Inner Medulla⁺⁺
Principal Investigator: Thomas Berl, MD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 DK66544-01
Amount: $250,000
Term: 2004-2009

Molecular Mechanism and Role of Corneal Adlehyde Dehydrogenase⁺⁺
Principal Investigator: Vasilis Vasiliou, PhD
Co-Investigator: Mark W. Duncan, PhD
Source: National Institutes of Health - RO1 EY011490-06
Amount: $225,000
Term: 2004-2009

Practical Utility of Desorption Mass Spectroscopy Techniques⁺⁺
Principal Investigator: Mark W. Duncan, PhD
Source: Pfizer, Inc.
Amount: $199,091
Term: 2004-2005

Modulation of Inflammation by Cholesterol and 3-Hydroxy-3 Coenzyme A Reductase Inhibitors: Role of the Lipid Raft⁺⁺
Principal Investigator: Michael Fessler, MD
Co-Investigator: Mark W. Duncan, PhD
Source: American Heart Association
Amount: $197,000
Term: 2002-2007

Proteomics for Testing Hypotheses about Down Syndrome⁺⁺
Principal Investigator: David Patterson, PhD
Principal Investigator: Mark W. Duncan, PhD (Consortium Subcontractor)
Source: National Institutes of Health - RO1 NS051539-01 A1
Amount: $77,000
Term: 2004-2008

Spirometry as an Outcome Measure in Preschool Children with Cystic Fibrosis
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Cystic Fibrosis Foundation
Amount: $920,504
Term: 2004-2007

Evaluation of Pulmonary Function Tests from Raised Lung Volumes as Outcome Measures for Clinical Trials in Infants with Cystic Fibrosis
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Seattle Children's Hospital and Regional Medical Center (Cystic Fibrosis Foundation)
Amount: $113,410
Term: 2003-2005

The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens
Principal Investigator: Gwendolyn S. Kerby, MD
Source: Genentech, Inc.
Amount: $3,045
Term: 2001-2004

Neuro-Immune Interactions in Developing Airways**
Principal Investigator: Gary L. Larsen, MD
Source: National Institutes of Health - R01 HL67818
Amount: $225,000/yr
Term: 2002-2006

Childhood Asthma Research and Education (CARE) Network
Principal Investigator: Stanley J. Szefler, MD
Co-Investigators: Ronina A. Covar, MD, and Gary L. Larsen, MD
Source: National Institutes of Health - HL64288
Amount: $600,000/yr
Term: 1999-2004

Noninvasive Biomarkers of Proteolytic Activity in Cystic Fibrosis
Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health - K23 RR018611-01
Amount: $653,400
Term: 2003-2008

Genetic Disorders of Mucociliary Clearance
Principal Investigator: Michael R. Knowles, MD
Site Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health - ORD #1 U54 RR019480-01
Amount: $6,250,000
Amount (Site Funding): $390,776
Term: 2004-2009

Cystic Fibrosis Foundation Fourth-Year Clinical Fellowship Grant
Breath Condensate Collection in Children with Cystic Fibrosis
Principal Investigator: Scott D. Sagel, MD
Sponsor: Frank J. Accurso, MD
Source: Cystic Fibrosis Foundation - SAGEL02A0
Amount: $62,600
Term: 2002-2003

Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis
Principal Investigator: Scott D. Sagel, MD
Source: National Institutes of Health, General Clinical Research Center, and INO Therapeutics, Inc. - INOT50
Amount: $34,020
Term: 2004-2006

SCOR Grant: The Impact of Injury on the Immature Pulmonary Circulationº
Principal Investigator: Kurt R. Stenmark, MD
Source: National Institutes of Health, National Heart, Lung and Blood Institute - P50 HL 57144
Amount: $6,415,929
Term: 2001-2006

• Project I: G-Proteins in Hypoxic Pulmonary Vascular Remodeling
  Principal Investigator: Kurt R. Stenmark, MD
  Amount: $2,076,662
  
• Project II: Inhaled NO and the Prevention of BPD
  Principal Investigator: Steven H. Abman, MD
  Co-Investigator: John P. Kinsella, MD
  Amount: $1,860,606
  
• Project III: Prx Homeobox Genes in Pulmonary Vascular Homeostasis
  Principal Investigator: Peter L. Jones, PhD
  Amount: $1,456,087
  
• Clinical Core
  Principal Investigator: John P. Kinsella, MD
  Co-Investigator: Steven H. Abman, MD
  Amount: $481,196
  
• Administrative Core
  Principal Investigator: Kurt R. Stenmark, MD
  Amount: $543,369
  

Inhaled Tobramycin in Young Cystic Fibrosis Patients
Site Principal Investigator: Jeffrey S. Wagener, MD
Source: National Institutes of Health - 1R01 DK57755-03
Amount: $291,241
Term: 2000-2003

A Phase I, Open-Label Safety and Tolerability Study of Oral TheraCLEC
Site Principal Investigator: Jeffrey S. Wagener, MD
Source: Altus Biologics (TheraCLEC)
Amount: $206,610
Term: 2003-2004

Duration of Antimicrobial Treatment Effect Following Administration of Tobramycin for Inhalation (TOBI) in Young Children with Cystic Fibrosis
Site Principal Investigator: Jeffrey S. Wagener, MD
Source: Cystic Fibrosis Foundation Therapeutics Network
Amount: $95,890
Term: 2002-2003

Assessment of Induced Sputum as a Tool to Evaluate Anti-Inflammatory Agents in Patients with Cystic Fibrosis
Principal Investigator: Jeffrey S. Wagener, MD
Source: Seattle Children's Hospital and Regional Medical Center
Amount (projected): $72,520
Term: 2004-2005

Bioavailability of Yasoo Formulation: A Pharmacokinetic Study
Principal Investigator: Jeffrey S. Wagener, MD
Source: Yasoo Health, Inc. - Yasoo-003
Amount (projected): $67,436
Term 2004-2005

Single-Dose Escalation Study to Evaluate Safety of Nasal Administration of CFTR001 Gene Transfer Vector to Subjects with Cystic Fibrosis
Site Principal Investigator: Jeffrey S. Wagener, MD
Source: Copernicus Therapeutics
Amount: $55,849
Term: 2002-2003

Epidemiologic Study of Cystic Fibrosis: A Multicenter, Longitudinal Follow-Up Study of Patients with Cystic Fibrosis for Monitoring Pulmonary Function, Pulmonary Exacerbations, and the Safety of Long-Term Treatment with Pulmozyme (Dornase Alfa)
Principal Investigator: Jeffrey S. Wagener, MD
Source: Genentech, Inc.
Amount: $21,625
Term: 1997-present

Clinical Targets in Hyperoxic Mitochondrial Injury
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health - 2 U01 HL56263
Amount: $667,257
Term: 1999-2004

Role of Hexokinase in Lung Adaptation to Oxidant Stress
Principal Investigator: Carl W. White, MD
Source: National Institutes of Health 2 R01 HL52732
Amount: $619,257/yr
Term: 1999-2004

Head CT in the Evaluation of 1st Afebrile Seizures
Principal Investigator: Lalit Bajaj, MD, MPH
Co-Investigators: Mark G. Roback, MD, Louis C. Hampers, MD, MBA, Carol Okada, MD, and Rebecca Fastle, MD
Term: 2000-2004

Postreduction Management of Intussusception
Principal Investigator: Lalit Bajaj, MD, MPH
Co-Investigators: Mark G. Roback, MD, and Shayne Bland, MSc
Term: 2000-2002

Emergency Medical Services for Children Partnership Grant
Principal Investigator: F. Keith Battan, MD
Source: US Department of Health and Human Services, Maternal and Child Health Bureau -
FLAEMS01-00250
Amount: $122,000
Term: 2000-2001

L.O.C.O. (Latinos Overcoming Cultural Obstacles) "Needs Assessment for The Children's Hospital"
Principal Investigator: Sonja Burbano-O'Leary, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Source: Colorado Chapter of the American Academy of Pediatrics
Amount: $3,000
Term: 2001

The Truth about Language Barriers
Principal Investigator: Sonja Burbano-O'Leary, MD
Co-Investigators: Louis C. Hampers, MD, MBA, and Stephen Federico, MD
Source: Colorado Chapter of the American Academy of Pediatrics
Amount: $3,000
Term: 2001-ongoing

Jungle Mobile: A Mobile Injury Prevention Project for Children
Principal Investigator: Kathryn D. Emery, MD
Co-Investigators: Allison Hawkes, MD, MS, Theresa Rapstine, RN, and Victoria Cassenbaugh, RN
Term: 1998-ongoing

A Screening Tool for the Detection of Child Abuse in the Emergency Department Setting
Joint Project with the Child Advocacy Protection Team
Principal Investigator: Kathryn D. Emery, MD
Term: 2001

Seat Belt and Car Safety Seat Use in SUVs
Primary Investigator: Kathryn D. Emery, MD
Co-Investigators: Lisa Hardin Van Bramer, MD, and Kevin Raines, MD
Source: National Highway Traffic Safety Administration - STNH22-01-H-05-257
Amount: $350,000
Term: 2001-2003

Childhood Injury Prevention Concerns of Migrant and Seasonal Farm Workers in Weld County
Principle Investigator: Kathryn D. Emery, MD
Co-Investigator: S. Glenn Faries, MD
Source: Colorado Injury Control Research Center
Amount: $15,000
Term: 2002-2003

Domestic Violence Policies in Pediatric Emergency Departments
Principle Investigator: Kathryn D. Emery, MD
Co-Investigators: Sheila Sullivan, MD, Andrew P. Sirotnak, MD, and Stephanie Stronks-Knapp, MD
Term: 2002-ongoing

Development of an Injury-Free Coalition for Kids
Principal Investigator: S. Glenn Faries, MD
Co-Investigator: Kathryn D. Emery, MD
Term: 2001-ongoing

Resident Education in the Emergency Department
Principal Investigator: S. Glenn Faries, MD
Term: 2002-ongoing

Need for Atropine for Emergent Pediatric Intubations
Principal Investigator: Rebecca Fastle, MD
Co-Investigator: Mark G. Roback, MD
Term: 1999-ongoing

Resuscitation Teaching at Primary Care Centers
Principal Investigator: Margaret Ferguson, MD
Co-Investigator: Mark G. Roback, MD
Term: 1998-ongoing

Utility of Anaerobic Blood Cultures in a Pediatric Emergency Department
Principal Investigator: Stephen Freedman, MD
Co-Investigator: Genie E. Roosevelt, MD, MPH
Term: 2001-2003

PEM Collaborative Research Committee, Cerebral Edema and DKA
Principal Investigator: Nicole Glaser, MD
Co-Investigator: Mark G. Roback, MD
Term: 1998-2001

Comparison of Oral Prednisone vs. Dexamethasone in Pediatric Asthma
Principal Investigator: Richard A. Greenberg, MD
Co-Investigators: Genie E. Roosevelt, MD, MPH, and Gwendolyn S. Kerby, MD
Term: 2002-ongoing

Peak Flow vs. Spirometry in Acute Asthma
Principal Investigator: David Gutglass, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 1997-ongoing

A.C.C.E.S.S. for Latinos: After-Hours Call Center and Extended Spanish Service
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigators: Lauren Clark, PhD, RN, and Stephen Berman, MD
Term: 2001-2002

The Impact of Interpreters on Resource Utilization in a Pediatric Emergency Department
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigator: Jennifer McNulty, MD
Term: 1999-2002

Physician-Based Practice Pattern Variations in the Management of AGE
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigator: Elizabeth Powell, MD, MPH
Term: 2001-ongoing

Practice Variation in the Management of Croup
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigators: S. Glenn Faries, MD, and Steven R. Poole, MD
Term: 1999-2002

Regional After-Hours Urgent Care Provided by a Tertiary Children's Hospital
Principal Investigator: Louis C. Hampers, MD, MBA
Co-Investigators: S. Glenn Faries, MD, and Steven R. Poole, MD
Term: 2001-2002

Booster Seat Project
Principal Investigator: Lisa Hardin Van Bramer, MD
Co-Investigator: Kathryn D. Emery, MD
Source: Emergency Medical Services and Kiwanis Pediatric Trauma Institute
Amount: $18,000
Term: 2001-2002

Association of Influenza with Bacterial Tracheitis
Principal Investigator: Ron L. Kaplan, MD
Co-Investigators: Mark G. Roback, MD, and Peggy Kelly, MD
Term: 2002-ongoing

Safety, Tolerability and Efficacy Study of Levalbuterol and Racemic Albuterol in Pediatric Patients Birth to 48 Months Old with Reactive Airways Disease in an Acute Setting
Principal Investigator: Gwendolyn S. Kerby, MD
Co-Investigator: S. Glenn Faries, MD
Term: 2001-2002

Effect of Ondansetron on Ketamine Sedation-Associated Vomiting
Principal Investigator: William T. Langston, MD
Co-Investigators: Joseph E. Wathen, MD, and Mark G. Roback, MD
Source: The Children's Hospital Research Institute
Amount: $5,000
Term: 2002-ongoing

Effect of Medical Spanish Classes on Satisfaction of Hispanic Patients in Pediatric Emergency Department
Principal Investigator: Suzanne Mazor, MD
Co-Investigators: Vidya Chande, MD, Louis C. Hampers, MD, MBA, and Steven Krug, MD
Term: 2000-2002

Interpretation of Traumatic Lumbar Punctures: Who Can Go Home?
Principal Investigator: Suzan Mazor, MD
Co-Investigators: Jennifer McNulty, MD, and Genie E. Roosevelt, MD, MPH
Term: 2001-ongoing

How Is Emergency Department Decision-Making Affected by the Existence of Reliable Follow-Up?
Principal Investigator: Jennifer McNulty, MD
Co-Investigators: Louis C. Hampers, MD, MBA, and Steven Krug, MD
Term: 1999-2001

Decision Rules for Obtaining Radiographs in Pediatric Knee Injuries
Principal Investigator: Brian Moore, MD
Co-Investigators: Louis C. Hampers, MD, MBA, and Kathryn Emery, MD
Term: 1998-ongoing

Indications for Knee Radiographs in Pediatric Patients with Acute Knee Injuries/Validation of a Clinical Decision Rule
Principal Investigator: Brian Moore, MD
Co-Investigators: Carol Turner, MD, and Kathryn D. Emery, MD
Term: 2000-ongoing

Correlation of Hemolysis with Facticous Hyperkalemia
Principal Investigator: Heather Owens, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 2002-ongoing

Acute Complication of Type 1 Diabetes in Children
Primary Investigator: Arleta B. Rewers, MD, PhD
Co-Investigators: Mark G. Roback, MD, and Joan P. Bothner, MD
Term: 2001-ongoing

Childhood Pedestrian Injuries
Primary Investigator: Arleta B. Rewers, MD, PhD
Term: 2002-ongoing

Femur Fractures and Associated Injuries
Principal Investigator: Arleta B. Rewers, MD, PhD
Co-Investigators: Kathryn D. Emery, MD, and F. Keith Battan, MD
Term: 2000-ongoing

Are Chest X-Rays Required for all First-Time Wheezers?
Principal Investigator: Mark G. Roback, MD
Co-Investigators: Mark E. Anderson, MD, and John D. Strain, MD
Term: 1998-ongoing

Comparison of the Efficacy and Safety of Sedation Drugs Used in a Pediatric Emergency Department
Principal Investigator: Mark G. Roback, MD
Co-Investigators: Joseph E. Wathen, MD, and Joan P. Bothner, MD
Term: 1999-ongoing

IV vs. IM Ketamine Sedation in the Pediatric Emergency Department
Principal Investigator: Mark G. Roback, MD
Co-Investigator: Joseph E. Wathen, MD
Source: The Children's Hospital Research Institute
Amount: $35,000
Term: 2000-ongoing

Pediatric Resuscitation Practice and Success Rate
Principal Investigator: Mark G. Roback, MD
Co-Investigator: Rebecca Fastle, MD
Term: 2000-ongoing

Predictors of Which Patients will Benefit from Observations vs. Hospital Admission
Principal Investigator: Genie E. Roosevelt, MD, MPH
Co-Investigator: S. Glenn Faries, MD
Term: 2002-ongoing

Randomized, Double-Blind Study of Intravenous Fluids With and Without Dextrose in the Treatment of Dehydration in Pediatric Patients with Vomiting and Ketosis
Principal Investigator: Genie E. Roosevelt, MD, MPH
Term: 2002-ongoing

The Effect of Dehydration on the QT Interval of Healthy Children
Principal Investigator: Carl Shaw, MD
Co-Investigators: Joseph E. Wathen, MD, and Michael S. Schaffer, MD
Term: 2001

The Prevalence of Urinary Tract Infections in Febrile Children with AGE
Principal Investigator: Carl Shaw, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 2002-ongoing

Use of Complementary Medicine in Pediatric Patients with Asthma
Principal Investigator: Alison Siegel Tothy, MD
Co-Investigator: Genie E. Roosevelt, MD, MPH
Term: 2001-2002

Associations between Insurance Type and Pediatric Admission Rate in Colorado, 1993-1999: Is Managed Care Fulfilling Its Promise?
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigators: Jill Joseph, MD, PhD, and James K. Todd, MD
Term: 2000-ongoing

Associations of Parental Depression and Child Health Outcomes
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigators: Allison Kempe, MD, John Steiner, MD, David Price, MD, and David Magid, MD
Term: 2002-ongoing

Comparison of the Longitudinal Marginal Cost, Morbidity and Mortality of Inflicted and Unintentional Head Injuries in Young Children in a Nationwide Sample of Children's Hospitals
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Anne Libby, PhD
Term: 2001-ongoing

Costs of Childhood Physical Abuse: Comparing Inflicted and Unintentional Head Injuries in Colorado Inpatients Under Three Years Old
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Anne Libby, PhD
Term: 2001-ongoing

Epidemiology of Pediatric Psychiatric Visits to US Emergency Departments, Based on the National Hospital Ambulatory Medical Care Survey 1995-1999
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Shayne Bland, MSc
Term: 2001-ongoing

Hospital-Level Predictors of Inefficiency Amongst Hospitalized Patients in New York State
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigators: Jill Joseph, MD, PhD, and Andrew Racine, MD, PhD
Term: 2000-ongoing

Management of Acute Gastroenteritis Visits to Emergency Departments Based on the National Hospital Ambulatory Medical Care Survey, 1995-1999
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Shayne Bland, MSc
Term: 2001-ongoing

Management of Bronchiolitis Visits to Emergency Departments Based on the National Hospital Ambulatory Medical Care Survey, 1993-1999
Principal Investigator: Marion R. Sills, MD, MPH
Co-Investigator: Shayne Bland, MSc
Term: 2001-ongoing

Comparison of Fascia Iliaca Compartment Nerve Block to Traditional Systemic Analgesics for Femur Fractures in a Pediatric Emergency Department
Principal Investigator: Joseph E. Wathen, MD
Co-Investigators: Glen Merritt, MD, Gaia Georgopoulos, MD, and F. Keith Battan, MD
Source: The Children's Hospital Research Institute
Amount: $17,594
Term: 2001-2004

Pediatric EKG Interpretation Accuracy by Pediatric Emergency Medicine Physicians
Principal Investigator: Joseph E. Wathen, MD
Co-Investigators: Arleta Rewers, MD, PhD, Angela Yetman MD, and Michael Schaffer MD
Term: 2001-ongoing

A Randomized Trial of Telephonic vs. On-Site Language Interpretation in a Pediatric ED
Principal Investigator: Ethan S. Wiener, MD
Co-Investigator: Louis C. Hampers, MD, MBA
Term: 2002-ongoing